Select
Home
About Us
Company Overview
Management Team
Board of Directors
Scientific Advisory Board
Corporate Governance
Development
Assets in Development
Deoxymab 3E10
PAT SC1
PAT SM6
PAT LM1
Investors
Analysts Reports
Annual Reports
Financial Reports 2019
Financial Reports 2018
Financial Reports 2017
Financial Reports 2016
News & Media
Market Announcements 2019
Market Announcements 2018
Market Announcements 2017
Newsletters
In the Media
Media Contact
Contact
ASX: PAB
LATEST NEWS
17 July 2019
Europe Grants Patent for Deoxymab 3E10
26 June 2019
Investor Update
30 May 2019
PAT-DX1 Reduces Brain Metastases and Enhances Low Dose Radiation Therapy
DEOXYMAB 3E10 INTRODUCTION
DEOXYMAB 3E10 PLATFORM
